| Investor | Soleus Capital Master Fund, L.P. |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Soleus Capital Master Fund, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | 13G | INSP / Inspire Medical Systems, Inc. | 1,470,748 | |||||
| 2026-05-27 | 13G | PALI / Palisade Bio, Inc. | 9,353,687 | |||||
| 2026-05-08 | 13G/A | CNTX / Context Therapeutics Inc. | 4,776,398 | 6,963,141 | ||||
| 2026-05-08 | 13G/A | GERNW / Geron Corporation - Equity Warrant | 41,508,659 | |||||
| 2026-05-08 | 13G/A | N2VC34 / NovoCure Limited - Depositary Receipt (Common Stock) | 10,492,391 | |||||
| 2026-05-08 | 13G/A | JSPR / Jasper Therapeutics, Inc. | 1,494,420 | 276,312 | ||||
| 2026-05-08 | 13G/A | BDSX / Biodesix, Inc. | 500,000 | 416,599 | ||||
| 2026-05-07 | 13G | RIGL / Rigel Pharmaceuticals, Inc. | 658,145 | 968,108 | ||||
| 2026-04-01 | 13G | VCEL / Vericel Corporation | 2,549,079 | |||||
| 2026-03-24 | 13G | CERS / Cerus Corporation | 9,828,700 | |||||
| 2026-03-09 | 13G | LUNG / Pulmonx Corporation | 2,665,100 | |||||
| 2026-03-03 | 13G | GERN / Geron Corporation | 33,008,659 | |||||
| 2026-02-19 | 13G | IMUX / Immunic, Inc. | 6,792,000 | |||||
| 2026-02-12 | 13G/A | NVCR / NovoCure Limited | 9,644,872 | 8,530,665 | ||||
| 2026-02-12 | 13G/A | ORGO / Organogenesis Holdings Inc. | 12,484,876 | 9,985,951 | ||||
| 2026-02-12 | 13G/A | TERN / Terns Pharmaceuticals, Inc. | 8,142,500 | 212,710 | ||||
| 2026-02-12 | 13G/A | CCCC / C4 Therapeutics, Inc. | 6,603,996 | 10,361,860 | ||||
| 2026-02-03 | 13G | CNTX / Context Therapeutics Inc. | 4,776,398 | |||||
| 2026-01-13 | 13G | BDSX / Biodesix, Inc. | 500,000 | |||||
| 2025-11-07 | 13G/A | STAA / STAAR Surgical Company | 2,562,893 | 500,000 | ||||
| 2025-11-07 | 13G/A | SRDX / Surmodics, Inc. | 739,060 | 0 | ||||
| 2025-11-07 | 13G/A | MURA / Mural Oncology plc | 1,323,877 | 0 | ||||
| 2025-11-07 | 13G/A | NVCR / NovoCure Limited | 6,904,302 | 9,644,872 | ||||
| 2025-08-05 | 13G/A | URGN / UroGen Pharma Ltd. | 2,325,000 | 2,185,000 | ||||
| 2025-08-05 | 13G/A | NVCR / NovoCure Limited | 5,521,414 | 6,904,302 | ||||
| 2025-08-05 | 13G/A | PRAX / Praxis Precision Medicines, Inc. | 1,017,740 | 966,740 | ||||
| 2025-08-05 | 13G/A | NPCE / NeuroPace, Inc. | 2,303,828 | |||||
| 2025-08-05 | 13G/A | MURA / Mural Oncology plc | 1,079,927 | 1,323,877 | ||||
| 2025-08-05 | 13G/A | RIGL / Rigel Pharmaceuticals, Inc. | 1,130,679 | 658,145 | ||||
| 2025-07-21 | 13D/A | EPIX / ESSA Pharma Inc. | 2,262,026 | 4,362,026 | ||||
| 2025-06-16 | 13G | URGN / UroGen Pharma Ltd. | 2,325,000 | |||||
| 2025-05-02 | 13G/A | AXGN / Axogen, Inc. | 3,005,943 | 1,446,117 | ||||
| 2025-04-23 | 13D/A | EPIX / ESSA Pharma Inc. | 2,262,026 | 2,262,026 | ||||
| 2025-04-16 | 13G | MURA / Mural Oncology plc | 1,079,927 | |||||
| 2025-04-15 | 13D | EPIX / ESSA Pharma Inc. | 2,262,026 | |||||
| 2025-04-11 | 13D/A | THTX / Theratechnologies Inc. | 5,188,876 | 4,801,375 | ||||
| 2025-04-01 | 13G | NVCR / NovoCure Limited | 5,521,414 | |||||
| 2025-03-28 | 13G | STAA / STAAR Surgical Company | 2,562,893 | |||||
| 2025-03-19 | 13G | PRAX / Praxis Precision Medicines, Inc. | 1,017,740 | |||||
| 2025-02-11 | 13G/A | CELC / Celcuity Inc. | 2,623,890 | 3,872,184 | ||||
| 2025-02-11 | 13G/A | ORGO / Organogenesis Holdings Inc. | 11,839,876 | 12,484,876 | ||||
| 2025-02-11 | 13G/A | JSPR / Jasper Therapeutics, Inc. | 987,096 | 1,494,420 | ||||
| 2025-02-11 | 13G/A | VSTM / Verastem, Inc. | 1,425,634 | 3,350,692 | ||||
| 2025-02-11 | 13G/A | TERN / Terns Pharmaceuticals, Inc. | 6,223,544 | 8,142,500 | ||||
| 2025-02-11 | 13G/A | RIGL / Rigel Pharmaceuticals, Inc. | 934,788 | 1,130,679 | ||||
| 2025-01-22 | 13G | SRDX / Surmodics, Inc. | 637,698 | 739,060 | ||||
| 2024-11-14 | 13G/A | ORGO / Organogenesis Holdings Inc. | 8,963,000 | 11,839,876 | ||||
| 2024-11-14 | 13G/A | SRDX / Surmodics, Inc. | 771,700 | 637,698 | ||||
| 2024-11-14 | 13G/A | VYNE / VYNE Therapeutics Inc. | 703,868 | 0 | ||||
| 2024-11-14 | 13G/A | IRMD / IRADIMED CORPORATION | 643,206 | 1,000 | ||||
| 2024-11-14 | 13G/A | RIGL / Rigel Pharmaceuticals, Inc. | 9,442,579 | 934,788 | ||||
| 2024-11-14 | 13G/A | CCCC / C4 Therapeutics, Inc. | 2,555,996 | 6,603,996 | ||||
| 2024-11-14 | 13G/A | TERN / Terns Pharmaceuticals, Inc. | 3,341,120 | 6,223,544 | ||||
| 2024-11-14 | 13G/A | AXGN / Axogen, Inc. | 2,595,815 | 3,005,943 | ||||
| 2024-06-07 | 13G | TERN / Terns Pharmaceuticals, Inc. | 3,341,120 | |||||
| 2024-02-09 | 13G/A | CELC / Celcuity Inc. | 2,285,554 | 2,623,890 | ||||
| 2024-02-08 | 13G/A | CALC / CalciMedica, Inc. | 783,904 | 1,105,016 | ||||
| 2024-02-05 | 13G | CCCC / C4 Therapeutics, Inc. | 1,835,996 | 2,555,996 | ||||
| 2024-02-02 | 13G/A | PIRS / Pieris Pharmaceuticals, Inc. | 4,000,000 | 0 | ||||
| 2024-02-02 | 13G/A | RIGL / Rigel Pharmaceuticals, Inc. | 9,223,015 | 9,442,579 | ||||
| 2024-02-02 | 13G/A | ORGO / Organogenesis Holdings Inc. | 7,363,063 | 8,963,000 | ||||
| 2024-02-02 | 13G/A | SRDX / Surmodics, Inc. | 775,311 | 771,700 | ||||
| 2024-02-02 | 13G/A | JSPR / Jasper Therapeutics, Inc. | 987,096 | |||||
| 2024-02-02 | 13G/A | VSTM / Verastem, Inc. | 1,297,369 | 1,425,634 | ||||
| 2024-02-02 | 13G/A | IRMD / IRADIMED CORPORATION | 745,004 | 643,206 | ||||
| 2024-02-02 | 13G/A | EDAP / EDAP TMS S.A. - Depositary Receipt (Common Stock) | 5,134,430 | 7,226,341 | ||||
| 2024-02-02 | 13G/A | VYNE / VYNE Therapeutics Inc. | 890,868 | 703,868 | ||||
| 2024-02-02 | 13G/A | DCTH / Delcath Systems, Inc. | 806,420 | 0 | ||||
| 2024-02-02 | 13G/A | CCCC / C4 Therapeutics, Inc. | 2,462,020 | 1,835,996 | ||||
| 2024-02-02 | 13G/A | AXGN / Axogen, Inc. | 3,541,298 | 2,595,815 | ||||
| 2024-01-26 | 13G | CALC / CalciMedica, Inc. | 783,904 | |||||
| 2023-11-28 | 13D | THTX / Theratechnologies Inc. | 5,188,876 | |||||
| 2023-11-02 | 13G | VYNE / VYNE Therapeutics Inc. | 890,868 | |||||
| 2023-08-16 | 13G | DCTH / Delcath Systems, Inc. | 806,420 | |||||
| 2023-08-11 | 13G | AXGN / Axogen, Inc. | 3,541,298 | |||||
| 2023-07-27 | 13G | VSTM / Verastem, Inc. | 1,297,369 | |||||
| 2023-04-14 | 13G | CCCC / C4 Therapeutics, Inc. | 2,462,020 | |||||
| 2023-02-22 | 13G | RIGL / Rigel Pharmaceuticals, Inc. | 9,223,015 | |||||
| 2023-02-14 | 13G/A | ORGO / Organogenesis Holdings Inc. | 6,626,063 | 7,363,063 | ||||
| 2023-02-14 | 13G/A | EDAP / EDAP TMS S.A. - Depositary Receipt (Common Stock) | 4,889,745 | 5,134,430 | ||||
| 2023-02-14 | 13G/A | SRDX / Surmodics, Inc. | 713,964 | 775,311 | ||||
| 2023-02-14 | 13G/A | IRMD / IRADIMED CORPORATION | 646,411 | 745,004 | ||||
| 2023-02-14 | 13G/A | APEN / Apollo Endosurgery Inc | 2,295,100 | 0 | ||||
| 2023-02-14 | 13G/A | THTX / Theratechnologies Inc. | 9,675,909 | 10,349,125 | ||||
| 2023-02-14 | 13G/A | CVRX / CVRx, Inc. | 1,044,040 | 1,014,640 | ||||
| 2023-02-14 | 13G/A | ADVM / Adverum Biotechnologies, Inc. | 4,982,789 | 0 | ||||
| 2023-02-14 | 13G/A | CELC / Celcuity Inc. | 948,389 | 2,285,554 | ||||
| 2023-01-30 | 13G | / JASPER THERAPEUTICS INC | 6,250,000 | |||||
| 2023-01-27 | 13G | PIRS / Pieris Pharmaceuticals, Inc. | 1,000,000 | 4,000,000 | ||||
| 2023-01-26 | 13G/A | PIRS / Pieris Pharmaceuticals, Inc. | 3,884,868 | 1,000,000 | ||||
| 2022-11-14 | 13G/A | THTX / Theratechnologies Inc. | 9,242,082 | 9,675,909 | ||||
| 2022-10-13 | 13G | ORGO / Organogenesis Holdings Inc. | 6,626,063 | |||||
| 2022-09-28 | 13G/A | EDAP / EDAP TMS S.A. - Depositary Receipt (Common Stock) | 3,148,609 | 4,889,745 | ||||
| 2022-09-02 | 13G | SRDX / Surmodics, Inc. | 713,964 | |||||
| 2022-09-02 | 13G | ADVM / Adverum Biotechnologies, Inc. | 4,982,789 | |||||
| 2022-09-01 | 13G | IRMD / IRADIMED CORPORATION | 646,411 | |||||
| 2022-05-18 | 13G | CELC / Celcuity Inc. | 948,389 | |||||
| 2022-04-29 | 13G | CVRX / CVRx, Inc. | 1,044,040 | |||||
| 2022-02-10 | 13G/A | EDAP / EDAP TMS S.A. - Depositary Receipt (Common Stock) | 1,824,566 | 3,148,609 | ||||
| 2022-02-10 | 13G/A | APEN / Apollo Endosurgery Inc | 2,085,497 | 2,295,100 | ||||
| 2022-02-10 | 13G/A | THTX / Theratechnologies Inc. | 7,425,382 | 9,242,082 | ||||
| 2022-01-27 | 13G | PIRS / Pieris Pharmaceuticals, Inc. | 3,884,868 | |||||
| 2021-12-20 | 13G | APEN / Apollo Endosurgery Inc | 2,085,497 | |||||
| 2021-04-28 | 13G | EDAP / EDAP TMS S.A. - Depositary Receipt (Common Stock) | 1,824,566 | 1,824,566 | ||||
| 2021-04-27 | 13G | EDAP / EDAP TMS S.A. - Depositary Receipt (Common Stock) | 1,824,566 | |||||
| 2021-02-23 | 13G | THTX / Theratechnologies Inc. | 7,425,382 |
